A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion — ASTRAL  

Brain Contusion Clinical Trial

Official title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion

Status Terminated

Clinical Trial Summary

The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo.

The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Brain Contusion
• Contusions

• NCT number: NCT03954041
• Study type: Interventional
• Source: Remedy Pharmaceuticals, Inc.
• Status: Terminated
• Phase: Phase 2
• Start date: October 6, 2019
• Completion date: June 27, 2023